When utilizing trastuzumab to treat unresectable GC, however, the heterogeneity of cancer cells in each patient should be taken into account; not all cancer cells are HER2-positive, and residual HER2-negative cancer cells are still at risk. This evidence concerns the gene ERBB2 and gastric cancer.